Cheniere Partners Reports Second Quarter 2025 Results and Reconfirms Full Year 2025 Distribution Guidance
HOUSTON–(BUSINESS WIRE)–Cheniere Energy Partners, L.P. (“Cheniere Partners”) (NYSE: CQP) today announced its financial results for second quarter... Read more.
Installed Building Products Reports Record Second Quarter 2025 Results; Declares Regular Quarterly Cash Dividend
COLUMBUS, Ohio–(BUSINESS WIRE)–Installed Building Products, Inc. (the “Company” or “IBP”) (NYSE: IBP), an industry-leading installer... Read more.
Cheniere Reports Second Quarter 2025 Results and Updates Full Year 2025 Financial Guidance
HOUSTON–(BUSINESS WIRE)–Cheniere Energy, Inc. (“Cheniere”) (NYSE: LNG) today announced its financial results for the second quarter 2025. SECOND... Read more.
Kustomer Raises $30M to Lead the AI-Native Future of Customer Experience
New funding led by Norwest will fuel Kustomer’s product innovation and development of their AI-native platform to further accelerate growth NEW YORK–(BUSINESS... Read more.
SelectQuote to Release Fiscal Fourth Quarter and Full Year 2025 Earnings on August 21
OVERLAND PARK, Kan.–(BUSINESS WIRE)–SelectQuote, Inc. (NYSE: SLQT), a leading distributor of Medicare insurance policies and owner of a rapidly growing... Read more.
Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline
Funding will advance Strand’s pipeline and mission to bring targeted, next-generation mRNA therapies to patients First-in-human solid tumor Phase 1 data from lead... Read more.
Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership
CorMedix to pay Melinta $300 million in upfront consideration, comprised of $260 million in cash and $40 million in CorMedix equity issued to Melinta shareholders... Read more.
Pagaya Reports Second Quarter and First Half 2025 Results
Second consecutive quarter of positive GAAP net income; raises full-year guidance Record performance across key metrics: Net income attributable to Pagaya shareholders... Read more.
Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance
– LINZESS® (Iinaclotide) U.S. net sales of $248 million in Q2 2025; EUTRx demand growth of 10% year-over-year – – Plans to align with FDA on confirmatory... Read more.
Advyzon Investment Management Launches Sphere, Featuring Professionally Managed Model Portfolios with Zero Strategist Fees
New platform allows advisors and clients to benefit from institutional-grade strategies at a low cost CHICAGO–(BUSINESS WIRE)–#CRM—Advyzon Investment... Read more.